Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12424663 | 0.87 | HSP90AA1 (0.31) | SCN9AHSP90AA1GABRA1GABRB2 | |
| SCHEMBL12424629 | 0.81 | SCN9A (0.36) | SCN9AHSP90AA1ALDH1A1GABRA1GABRB2 | |
| SCHEMBL25836768 | 0.78 | HSP90AA1 (0.36) | HSP90AA1HPGDALDH1A1L3MBTL1 | |
| SCHEMBL12424673 | 0.76 | CNR1 (0.35) | HPGD | |
| SCHEMBL12424664 | 0.70 | HSP90AA1 (0.35) | HSP90AA1HPGDALDH1A1L3MBTL1 | |
| SCHEMBL10018217 | 0.70 | HSP90AA1 (0.37) | HSP90AA1HPGDALDH1A1L3MBTL1 | |
| SCHEMBL12424667 | 0.69 | AURKA (0.34) | HSP90AA1HPGDALDH1A1L3MBTL1 | |
| SCHEMBL12424598 | 0.69 | CNR2 (0.35) | HPGDALDH1A1 | |
| SCHEMBL3920058 | 0.66 | PDK2 (0.36) | HPGDALDH1A1 | |
| SCHEMBL28683000 | 0.66 | KCNH2 (0.37) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7976739-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7976739-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20100230649-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100230649-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2055698-A1 | CHROMENE COMPOUND | Tokuyama Corporation (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100230649-A1 | CHROMENE COMPOUND | CCNT1, RB1, H1-0 | SCN9A 1556/4885HSP90AA1 4086/4885HPGD 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.